- About MHRP
- International Network
- Prevention, Care & Treatment
- News & Publications
An Army-sponsored phase III clinical trial (RV144) involving more than 16,000 adult volunteers in Thailand showed that an investigational HIV vaccine regimen was safe and modestly effective in preventing HIV infection.
RV217: A multi-site research study on acute HIV infections
RV254: An early HIV infection study in Thailand
RV262: Phase I study to evaluate a combination DNA prime/MVA vector boost vaccine regimen
RV305: Immunogenicity study evaluating extended boosting regimens using the same vaccine components used in RV144
RV329: African Cohort Study
Survivors of the 2007-08 Bundibugyo ebolavirus (BDBV) outbreak in Uganda experienced negative health effects that persisted more than two years after the outbreak claimed 39 lives, according to findings from an MHRP study published in the Lancet ID today.
In a new paper, published in the journal BBA Biomembranes, MHRP researcher and liposome pioneer Dr. Carl Alving and his team deconstruct the underlying science behind the physical structure of the world’s most potent vaccine adjuvant.
Findings from a WRAIR/NIAID led Ebola vaccine clinical trail were published in the New England Journal of Medicine today, highlighting that the vaccine candidate is safe and elicits a robust immune response.
A clinical trial called HVTN 100 has been launched in South Africa to study an investigational HIV vaccine regimen for safety and the immune responses it generates in study participant
A new Phase Ib clinical trial of two experimental Ebola vaccines began today in Kampala, Uganda.
The Role of Research Nurses in HIV Research
Nurses play an integral role on the research team of HIV studies and vaccine clinical trials. Read more about two hard-working nurses who are helping MHRP in the quest to find an end to AIDS.
Video: Early HIV Infection Study Offers Insight Into the Initial Stages of HIV Infection
MHRP researchers and Thai collaborators are leading the way in acute infection studies. One study, called RV254/SEARCH 010 is providing knowledge about the earliest HIV events that may provide clues to developing an effective HIV vaccine or even help identify ways to achieve a functional cure.